Navigation Links
CorMedix, Inc. Granted Extension of NYSE-MKT Listing
Date:7/24/2014

BRIDGEWATER, N.J., July 24, 2014 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announces receipt of notice on July 18, 2014 from the NYSE MKT LLC (NYSE-MKTS) that the NYSE-MKT has accepted the CorMedix plan to regain compliance with continued listing standards of the NYSE-MKT. As a result, the NYSE-MKT is continuing the Company's listing and has granted the Company an extension until May 31, 2015 to regain compliance with the continued listing standards of the NYSE-MKT.  The Company will be subject to periodic review by the NYSE-MKT during the extended plan period.

CorMedix previously received notice from the NYSE-MKT that it was not in compliance with NYSE-MKT's continued listing standards set forth in Section 1003(a)(i) of the NYSE-MKT Company Guide because CorMedix reported stockholders' equity of less than $2,000,000 as of March 31, 2014 and net losses in two of its three most recent fiscal years and Section 1003(a)(ii) of the Company Guide because CorMedix reported stockholder's equity of less than $4,000,000 as of March 31, 2014 and net losses in three of its four most recent fiscal years.

New Executives

In addition, CorMedix announces the addition of two executives to the management team. Harry O'Grady joins the Company as Chief Financial Officer and Dr. Antony Pfaffle transitions from Interim Chief Scientific Officer to a full time Chief Scientific Officer.

Randy Milby, Chief Executive Officer of CorMedix, stated, "The steps to regain compliance with the NYSE-MKT listing standards are well underway and we feel confident CorMedix will be in compliance by the end of the extension period. In addition, I am very pleased to welcome Harry O'Grady and Dr. Antony Pfaffle to full time positions on the CorMedix management team.  Harry brings an extensive hands-on operational financial skill set to the Company.  Dr. Pfaffle has been an instrumental figure within CorMedix and is leading the clinical development of Neutrolin. We are pleased to have them focused on the success of CorMedix."

Earnings Call

The Company announces the Second Quarter Conference Call on August 15, 2014 at 9:00 am. The dial in number is: 866-866-1333 or +1 404-260-1421. All participants who dial in will need to give the operator the following information:

  • Access Code 5380924
  • Company Name
  • Caller ID

About CorMedix Inc.

CorMedix Inc. is a commercial-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. CorMedix's first commercial product in Germany is Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients.  Please see the company's website at www.cormedix.com for additional information.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or CorMedix's prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including: the acceptance by the FDA of the protocol for the planned Phase 3 trial for Neutrolin; obtaining regulatory approvals to conduct clinical trials and to commercialize CorMedix's product candidates, including marketing of Neutrolin® in countries other than Germany; the risks associated with the launch of Neutrolin® in Europe and other markets; CorMedix's ability to maintain its listing on the NYSE MKT; the risks and uncertainties associated with CorMedix's ability to manage its limited cash resources; the outcome of clinical trials of CorMedix's product candidates and whether they demonstrate these candidates' safety and effectiveness; CorMedix's ability to enter into and maintain collaborations with third parties for its development and marketing programs; CorMedix's dependence on its collaborations and its license relationships; achieving milestones under CorMedix's collaborations; obtaining additional financing to support CorMedix's research and development and clinical activities and operations; CorMedix's dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers, sales and marketing organizations, and consultants; and protecting the intellectual property developed by or licensed to CorMedix. These and other risks are described in greater detail in CorMedix's filings with the SEC, copies of which are available free of charge at the SEC's website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.


'/>"/>
SOURCE CorMedix Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
2. Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7)
3. CE Mark Granted for Wound Spray Based on Sangui Patent
4. Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
5. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
6. ERT Granted Patents on Clinical Trial Participant Compliance
7. Revolutionary Tetrapod Quantum Dot Synthesis US Patent Granted
8. Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438
9. Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol"
10. Factor Bioscience Granted First U.S. Patent for RNA-Based Reprogramming Technology
11. Star Scientific Announces Patent Claims to Anatabine Citrate to be Granted by PTO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2016 More than $4.3 million was raised last ... DHMD ). The gala was held at the American Museum ... and honored Alan Alda and ... and medicine and the public understanding of science. Since the ... event has raised $40 million for the Laboratory,s research and ...
(Date:12/2/2016)... THOUSAND OAKS, Calif. , Dec. 2, 2016 ... AGN ) today announced the submission of a ... for ABP 215, a biosimilar candidate to Avastin ® ... biosimilar application submitted to the EMA. "The ... milestone as Amgen seeks to expand our oncology portfolio," said ...
(Date:12/2/2016)... Research and Markets has announced the addition of ... to their offering. ... , , An ... is anticipated. Nanotechnology will be applied at all stages of ... applications in clinical trials. Many of the assays based on ...
(Date:12/2/2016)... Texas (PRWEB) , ... December ... ... that it will share findings demonstrating the value of DNA microarray comparative ... at this year’s San Antonio Breast Cancer Symposium. Using molecular test results ...
Breaking Biology Technology:
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/9/2016)... TURKU, Finland , June 9, 2016 ... French National Police deploy Teleste,s video security solution to ensure ... France during the major tournament ... and data communications systems and services, announced today that its ... Police Prefecture to back up public safety across ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
Breaking Biology News(10 mins):